
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is attractive because it has advanced COMP360 from strong clinical validation into a rolling NDA that is already under FDA review, with a potential 1H27 launch supported by federal and state rescheduling momentum and a favorable expected label. The fundamental case is reinforced by two positive Phase 3 TRD trials, supportive retreatment evidence, and a large commercial footprint of more than 8,000 interventional psychiatry centers, while management is already building reimbursement, REMS, and field infrastructure. Financially, the company ended 3Q26 with $444.0 million in cash, minimal net loss of $9.8 million, and runway into 2028, giving it the balance-sheet strength to fund launch preparation and its Phase 2b/3 PTSD program.
Bears say
Compass Pathways is vulnerable to competitive pressure because if other developers generate compelling data in the same settings where COMP360 psilocybin is expected to compete, investor enthusiasm and market share expectations could weaken. With the company still centered on a single proprietary program and one operating segment, its valuation is heavily dependent on the clinical success and differentiation of COMP360 rather than on a diversified revenue base. That concentration makes the stock fundamentally risky, since any loss of relative efficacy, safety, or momentum versus peers could modestly pressure CMPS shares.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About COMPASS Pathways (CMPS) Forecast
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares